Bionexus Gene Lab Stock Performance
| BGLC Stock | USD 4.90 0.02 0.41% |
BioNexus Gene holds a performance score of 8 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 8.87, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioNexus Gene will likely underperform. Use BioNexus Gene total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to analyze future returns on BioNexus Gene.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in BioNexus Gene Lab are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of rather fragile essential indicators, BioNexus Gene exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.41 | Five Day Return 1.03 | Year To Date Return 22.81 | Ten Year Return (98.14) | All Time Return (98.14) |
Last Split Factor 1:10 | Last Split Date 2025-04-07 |
1 | BioNexus Gene Lab Corp. Regains Nasdaq Compliance, Signaling Strategic Stability and Growth Readiness | 04/30/2025 |
2 | 12 Industrials Stocks Moving In Tuesdays After-Market Session | 07/01/2025 |
3 | Why Datadog Shares Are Trading Higher By Over 10 Here Are 20 Stocks Moving Premarket | 07/03/2025 |
4 | 12 Industrials Stocks Moving In Thursdays Intraday Session | 07/17/2025 |
5 | BioNexus Gene Lab Corp. Stock Analysis and Forecast - High-margin investment plays - Autocar Professional | 07/23/2025 |
| Begin Period Cash Flow | 4.5 M | |
| Total Cashflows From Investing Activities | 418.2 K |
BioNexus Gene Relative Risk vs. Return Landscape
If you would invest 271.00 in BioNexus Gene Lab on April 28, 2025 and sell it today you would earn a total of 219.00 from holding BioNexus Gene Lab or generate 80.81% return on investment over 90 days. BioNexus Gene Lab is currently generating 3.7566% in daily expected returns and assumes 35.2669% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than BioNexus, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioNexus Gene Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioNexus Gene's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioNexus Gene Lab, and traders can use it to determine the average amount a BioNexus Gene's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1065
| Best Portfolio | Best Equity | |||
| Good Returns | BGLC | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 35.27 actual daily | 96 96% of assets are less volatile |
Expected Return
| 3.76 actual daily | 75 75% of assets have lower returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average BioNexus Gene is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioNexus Gene by adding it to a well-diversified portfolio.
BioNexus Gene Fundamentals Growth
BioNexus Stock prices reflect investors' perceptions of the future prospects and financial health of BioNexus Gene, and BioNexus Gene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioNexus Stock performance.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.23) % | ||||
| Operating Margin | (0.27) % | ||||
| Current Valuation | 5.41 M | ||||
| Shares Outstanding | 1.8 M | ||||
| Price To Earning | 350.00 X | ||||
| Price To Book | 1.13 X | ||||
| Price To Sales | 0.95 X | ||||
| Revenue | 9.51 M | ||||
| Gross Profit | 1.27 M | ||||
| EBITDA | (1.42 M) | ||||
| Net Income | (1.6 M) | ||||
| Cash And Equivalents | 1.34 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 210.56 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 3.84 X | ||||
| Book Value Per Share | 4.33 X | ||||
| Cash Flow From Operations | (2.23 M) | ||||
| Earnings Per Share | (1.19) X | ||||
| Market Capitalization | 8.8 M | ||||
| Total Asset | 10.43 M | ||||
| Retained Earnings | (3.44 M) | ||||
| Working Capital | 5.48 M | ||||
About BioNexus Gene Performance
By analyzing BioNexus Gene's fundamental ratios, stakeholders can gain valuable insights into BioNexus Gene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioNexus Gene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioNexus Gene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 61.65 | 98.57 | |
| Return On Tangible Assets | (0.15) | (0.16) | |
| Return On Capital Employed | (0.19) | (0.19) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.19) | (0.20) |
Things to note about BioNexus Gene Lab performance evaluation
Checking the ongoing alerts about BioNexus Gene for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioNexus Gene Lab help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioNexus Gene Lab is way too risky over 90 days horizon | |
| BioNexus Gene Lab appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 9.51 M. Net Loss for the year was (1.6 M) with profit before overhead, payroll, taxes, and interest of 1.27 M. | |
| BioNexus Gene Lab currently holds about 1.34 M in cash with (2.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| BioNexus Gene Lab has a frail financial position based on the latest SEC disclosures | |
| Roughly 51.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: BioNexus Gene Lab Corp. Stock Analysis and Forecast - High-margin investment plays - Autocar Professional |
- Analyzing BioNexus Gene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioNexus Gene's stock is overvalued or undervalued compared to its peers.
- Examining BioNexus Gene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioNexus Gene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioNexus Gene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioNexus Gene's stock. These opinions can provide insight into BioNexus Gene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioNexus Stock analysis
When running BioNexus Gene's price analysis, check to measure BioNexus Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNexus Gene is operating at the current time. Most of BioNexus Gene's value examination focuses on studying past and present price action to predict the probability of BioNexus Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNexus Gene's price. Additionally, you may evaluate how the addition of BioNexus Gene to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |